NOVRAD Drug Patent Profile
✉ Email this page to a colleague
When do Novrad patents expire, and when can generic versions of Novrad launch?
Novrad is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in NOVRAD is levopropoxyphene napsylate anhydrous. Additional details are available on the levopropoxyphene napsylate anhydrous profile page.
Summary for NOVRAD
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 9 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NOVRAD at DailyMed |
US Patents and Regulatory Information for NOVRAD
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | NOVRAD | levopropoxyphene napsylate anhydrous | CAPSULE;ORAL | 012928-006 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | NOVRAD | levopropoxyphene napsylate anhydrous | CAPSULE;ORAL | 012928-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | NOVRAD | levopropoxyphene napsylate anhydrous | SUSPENSION;ORAL | 012928-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |